Letrozole Pharmacenter

Letrozole, the active ingredient in Letrozole Pharmacenter, is a aromatase inhibitor presented as a tablet for oral use. It reduces estrogen production to treat hormone receptor‑positive breast cancer in postmenopausal women, helping to slow tumor growth and improve clinical outcomes.

GNH USA supplies Letrozole Pharmacenter as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide, providing reliable access to this essential antineoplastic agent across global markets.

Letrozole acts on estrogen‑dependent pathways and is employed in the management of breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen levels to inhibit tumor proliferation. - Adjuvant therapy for early‑stage breast cancer: Decreases risk of disease recurrence after surgery. - Metastatic breast cancer (postmenopausal): Controls disease progression by limiting estrogen‑driven growth.

Letrozole may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Joint and muscle pain: Discomfort in joints, muscles, or the back. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head. - Dizziness: Light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, or elevated liver enzymes. - Bone fractures: Increased risk due to reduced bone mineral density. - Pulmonary embolism: Sudden shortness of breath, chest pain, or coughing up blood. - Allergic reactions: Rash, itching, swelling, or difficulty breathing. - Severe hypertension: Markedly high blood pressure requiring urgent care. - Cardiovascular events: Heart attack or stroke in susceptible patients.

Before initiating Letrozole therapy, several safety considerations should be addressed. - Bone health monitoring: Assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: Perform baseline liver enzyme tests and repeat as clinically indicated. - Cardiovascular risk evaluation: Review history of hypertension, thromboembolic disease, or cardiac events. - Pregnancy contraindication: Do not use in pregnant or nursing women; ensure effective contraception. - Premenopausal status: Avoid in women with active ovarian function unless ovarian suppression is confirmed. - Drug interaction vigilance: Review concomitant medications that may alter letrozole metabolism. - Store at ambient temperature below 25°C: Keep in the original packaging, protect from moisture and light.

Letrozole may interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Tamoxifen: Antagonistic effect reducing therapeutic benefit. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): May increase letrozole plasma levels. - Strong CYP2C9 inhibitors (e.g., fluconazole): Can elevate drug exposure and toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): May lower letrozole concentrations, reducing efficacy. - CYP2A6 inhibitors (e.g., methoxsalen): May modestly raise letrozole levels. - Warfarin: Potentially increased INR; monitor coagulation parameters.